Immune effector cell-associated neurotoxicity syndrome Definition : Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a clinical and neuropsychiatric syndrome associated with trea...
CAR-T cell therapy is an effective cancer therapy for multiple refractory/relapsed hematologic malignancies but is associated with substantial toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). Improved detection and assessment of ICANS could improve management and allow ...
However, there are a number of things that could go wrong. One of the key risks of CAR-T therapy is cytokine release syndrome, where the immune system has an overly strong response to the infused CAR T cells. Another risk is immune effector cell associated neurotoxicity, which causes side ...
Safety: The patient developed only grade 1 cytokine release syndrome (CRS), but had no immune effector cell-associated neurotoxicity syndrome (ICANS). Only transient hemocytopenia was observed. No new safety risks were found compared to the safety profile in the studies of multiple myeloma indicatio...
CAR T-cell therapy (CART) has revolutionized the treatment landscape of aggressive B cell lymphoma (aBCL) in the relapsed/refractory (r/r) setting, including high-risk groups such as high grade B cell lymphoma (HGBCL), primary refractory disease, and chemo-resistant relapses. To date, howev...
The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.Previous article in issue Next article in issue...
ACZ, acetazolamide; AE, adverse event; DLT, dose-limiting toxicity; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ICU, intensive care unit; TEAE, treatment-emergent adverse event. PRESENTED BY: Rodabe N Amaria, The University of Texas MD Anderson ...
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The pre-infusion tumor burden is associated with CRS.....
regulated by heat shock was reversible and can be terminated simply through switching off the iWarm to avoid the unwanted side effects, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome that are commonly encountered in other cell therapies, such as CAR-T ...
R. et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity 50, 253–271 (2019). CAS PubMed Google Scholar Keren-Shaul, H. et al. A unique microglia type associated with restricting development of ...